

FREEDOM OF INFORMATION SUMMARY

NEW ANIMAL DRUG APPLICATION

NADA 094-170

PHENYLBUTAZONE TABLETS 200 MG

For the relief of inflammatory conditions associated with the musculoskeletal system in dogs.

Sponsored by:

PHOENIX SCIENTIFIC, INC.

FREEDOM OF INFORMATION SUMMARY

Supplement to NADA 094-170 -Phenylbutazone tablets 200mg

1. GENERAL INFORMATION:

NADA Number: 094-170

NADA Sponsor: Phoenix Scientific, Inc.
3915 South 48th Street Terrace
P.O. Box 6457
St. Joseph, MO 64506-0457

Generic Name: Phenylbutazone Tablets

Trade Name: Phenylbutazone Tablets USP 200 mg

How Dispensed: Rx

Effect of Supplement: To provide for a 200 mg phenylbutazone tablet

2. INDICATIONS FOR USE:

For relief of inflammatory conditions associated with the musculoskeletal system in dogs.

3. DOSAGE:

ORALLY 20 mg/lb. of body weight (200 mg/10 lb.) in three divided doses daily. Maximum dose is 800 mg per day regardless of weight.

Use a relatively high dose for the first 48 hours, then reduce gradually to a maintenance dose.

Maintain lowest dose capable of producing desired clinical response.

4. EFFECTIVENESS:

The 200 mg tablet is identical to the previously approved 100 mg tablet with respect to its excipients and the proportion of active to inactive ingredients. The sole differences between the two formulations are tablet strength and shape.

Since phenylbutazone is a 'Class II' (low solubility, high permeability)

compound [refer to Amidon, GL., Lennernas, H., Shah, VP, and Crison, JR (1995). A theoretical basis for a biopharmaceutic drug classification: the correlation of *in vitro* drug product dissolution and *in vivo* bioavailability. *Pharm. Res.*, 12: 413-420], and given the similarity in the approved and proposed tablet formulations, it was determined that comparative *in vitro* dissolution data could provide a surrogate for the demonstration of *in vivo* bioequivalence. Accordingly, in lieu of *in vivo* bioequivalence testing, an *in vitro* comparison was generated for the two tablet sizes (FDA Guidance for Industry – August 1997-Dissolution Testing of Immediate Release Solid Oral Dosage Forms) at Phoenix Scientific, Inc.

Dissolution testing was conducted on 12 units of the 100 mg and 200 mg strength tablets. Samples were collected from each vessel in each dissolution test at 10, 12.5, 15, 17.5, 20, 25, 30 and 45 minutes.

Percent Dissolved:

Strength	Times (in minutes)							
	10.0	12.5	15.0	17.5	20.0	25.0	30.0	45.0
100mg								
Average	55.84	64.09	70.24	75.23	79.20	85.52	90.36	99.62
%CV	13.6	11.0	7.8	6.6	5.1	4.3	3.6	3.3
200mg								
Average	64.94	69.80	75.19	80.38	83.58	88.81	92.88	98.90
%CV	12.0	8.9	8.0	6.8	5.5	4.3	3.7	2.7

As per the FDA/CDER guidance, the assessment of profile comparability was achieved through estimation of the similarity factor (f_2). The f_2 metric is a logarithmic reciprocal square root transformation of the sum of squared error that provides a measure of the similarity in the percent dissolved between two curves and is calculated as follows:

$$f_2 = 50 * \log \left\{ \left[1 + \left(\frac{1}{n} \right) \sum_{t=1}^n (R_t - T_t)^2 \right]^{-0.5} * 100 \right\}$$

where n = number of time points

R_t = dissolution value of the reference batch at time t

T_t = the dissolution value of the test batch at time t.

Restrictions associated with the use of the f_2 estimate include:

- The dissolution measurements of the test and reference batches must be

made under exactly the same conditions.

- There should only be one measurement considered after either product has achieved 85% dissolution.
- The percent coefficient of variation at the earliest points (e.g., 15 minutes) should not exceed 20%, and the %CV should not exceed 10% at all other time points.

In keeping with these constraints, the 30 and 45 minute results were not considered in the estimation of the similarity factor. Furthermore, the coefficients of variation associated with the 10 and 12.5 minute samples were less than 20% and the coefficients of variation for the 15 to 25 minute samples were less than 10%. Finally, the test and reference batches were made under exactly the same conditions. Therefore, all restrictions associated with the use of the f_2 criteria for the profile comparison were met.

For this dataset, the Similarity Factor (f_2) = 61.80

For curves to be considered similar, the f_2 value should be greater than or equal to 50. This critical value was achieved, indicating that the change in tablet size from 100 mg to 200 mg did not significantly affect the dissolution of the formula. Accordingly, since phenylbutazone is a Class II compound, these data confirm that the rate and extent of phenylbutazone *in vivo* absorption from the 100 mg and 200 mg strength tablets will be comparable when administered in the same mg/kg b.w. dose.

5. ANIMAL SAFETY:

The 200 mg tablet is the same formula as the previously approved 100 mg tablet but produced as a larger tablet of twice the weight as discussed under **effectiveness**. Refer to NADA 094-170 original Freedom of Information Summary dated January 1, 1974.

6. HUMAN SAFETY:

Human Safety Relative to Food Consumption: Data on human food safety, pertaining to consumption of drug residues in food, were not required for approval of this NADA supplement. This drug is to be labeled for the use in dogs, which are non-food animals.

Human Safety Relative to Possession, Handling and Administration: Labeling contains adequate caution/warning statements.

7. AGENCY CONCLUSIONS:

Data in support of this supplement to NADA 094-170 comply with the requirements of Section 512 of the Act and Section 514 of the implementing regulations. The data demonstrate that 200 mg Phenylbutazone Tablets, when used under labeled conditions are safe and effective for its intended use.

Phenylbutazone Tablets are restricted to use by or on the order of a licensed veterinarian because professional expertise and proper diagnosis are required to determine when a dog has an inflammatory condition associated with the musculoskeletal system warranting the use of such a drug and monitoring its safe use.

Under section 512(c)(2)(F)(iii) of the FDCA, this approval for non-food producing animals qualifies for three years of marketing exclusivity beginning on the date of approval because the supplemental application contains substantial evidence of the effectiveness of the drug involved, or any studies of animal safety, required for the approval of the application and conducted or sponsored by the applicant. The three years of marketing exclusivity applies to only the 200 mg tablet, for which the supplemental application was approved.

8. Labeling (Attached)

A. Bottle Label

B. Package Insert